Listed times are in Central European Summer Time (CEST)

REGISTRATION

Light refreshments will be served at 12:00

CONFERENCE WELCOME

Session 1: Unveiling the biology beneath the biomarkers: Mechanisms driving liquid biopsy signals

Chair: Ellen Heitzer

OPENING KEYNOTE LECTURE

Efrat Shema Weizmann Institute of Science, Israel

'Single-molecule epigenetic analysis of plasma-circulating nucleosomes for cancer diagnosis'

Q&A 13:40-13:55

Amin El-Heliebi Med Uni Graz, Austria

'Integrating liquid biopsy and spatial transcriptomics for understanding ctDNA release'

Q&A 14:15-14:25

Sangmi Lee Harvard Medical School, USA

Proferred Paper 1: 'Mechanistic interpretation of cfDNA fragmentation topography through joint deconvolution of fragmentation processes and tissue composition with cfVista'

Q&A 14:35-14:40

EXHIBITOR INTRODUCTIONS

COFFEE BREAK, EXHIBITION AND SOLO TRAVELLERS' MEET-UP

Remond Fijneman NKI, Netherlands

'Impact of tumor location and host factors on ctDNA shedding'

Q&A 15:50-16:00

Mischa Steketee Amsterdam UMC, Netherlands

Proferred Paper 2: 'Tumor-Informed Deconvolution of Circulating Extracellular Vesicle RNA in Large B Cell Lymphoma Patients Reveals On-treatment Tumor-Microenvironment Evolution'

Q&A 16:10-16:15

Marie Bernkopf St. Anna Children's Cancer Research Institute, Austria

Proffered Paper 3: 'Sensitive detection of relapse and immunotherapy targets by blood and bone marrow multi-modal liquid biopsy analysis in high-risk neuroblastoma'

Q&A: 16:25-16:30

POSTER SPOTLIGHTS

Wenhan Chen (Australia) 'Improving paediatric cancer care by leveraging a new ultra-sensitive ctDNA assay'

Kate Glennon (Germany) 'Nucleosomal profiling infers ER status in longitudinal breast cancer liquid biopsies'

Parisa Mapar (Netherlands) 'Cell-Free DNA Genomic and Fragmentomic Features for Early Outcome Prediction in Large B-Cell Lymphoma'

INDUSTRY SYMPOSIUM - biomodal

Tom Charlesworth Director of Market Strategy & Corporate Development, biomodal

'Single stranded 6-base workflow optimises discovery of integrated genetic, epigenetic and fragmentomic biomarkers for sensitive ctDNA detection'

PANEL DISCUSSION

'Where is liquid biopsy heading in the next 5–10 years? Clinical implementation, standardization and regulatory challenges'

WELCOME RECEPTION

POSTER DISCUSSION SESSION 1

Led by members of the Scientific Programme Committee

Listed times are in Central European Summer Time (CEST)

EARLY POSTER VIEWING

Chair: Claus Lindbjerg Andersen

INDUSTRY SPOTLIGHT - Ultima Genomics

Alex Watkins Staff Field Applications Scientist

'Using Ultima Genomics technology to detect minimal residual disease'

Session 2: Tracking the unseen: Liquid biopsies in advanced and metastatic cancer

Karen-Lise Garm Spindler Aarhus University, Denmark

'Using ctDNA for response evaluation in solid tumors – a paradigm shift in medical oncology?'

Q&A 9:20-9:30

Peter Ulz Medical University Graz, Austria

Proferred Paper 4: 'Landscape of somatic copy-number alterations in advanced breast, prostate and colorectal cancers by longitudinal shallow whole-genome sequencing of cell-free DNA'

Q&A 09:40-09:45

Ellen Heitzer Meduni Graz, Austria

'Signal vs Noise: The Reality of ctDNA in Advanced Disease'

Q&A 10:05-10:15

Irene Casanova VHIO, Spain

'EV-enhanced liquid biopsy for tumor dynamics in metastatic Prostate Cancer'

Q&A 10:35-10:45

COFFEE BREAK AND EXHIBITION

François Clément Bidard Institut Curie & UVSQ/Université Paris-Saclay, France

'Intercepting late resistance to therapy with ctDNA: ESR1 mutations and beyond'

Q&A 11:35-11:45

Galatea Kallergi University of Patras, Greece

Proferred Paper 5: 'Unraveling the Phenotypic Heterogeneity of Tumor-Derived Cells in the Bloodstream of Pancreatic Cancer Patients'

Q&A 11:55-12:00

POSTER SPOTLIGHTS

Kyle Smith (USA) 'M-PACT-GLOBAL: a pediatric pan-cancer classifier for cell-free DNA methylomes'

Roma Sunder (Spain) 'Longitudinal multimodal liquid biopsy profiling to characterize treatment response dynamics in metastatic Prostate Cancer: Interim results from the MARION clinical study'

INDUSTRY SYMPOSIUM - Becton Dickinson

Markus Wolf PreAnalytix, Senior Scientist R&D

'From Blood Draw to Insight: Key Considerations in Preparing Diagnostic Liquid Biopsy Specimens for ccfDNA Analysis'

LUNCH

POSTER DISCUSSION SESSION 2

Led by members of the Scientific Programme Committee

Session 3: Frontiers in liquid biopsy technology: From fragmentomics to functional readouts

Chair: Nikolas Stoecklein

Mette Aaegebeck University of Copenhagen, Denmark

'Oncofetal Chondroitin Sulfate: A circulating biomarker on tumour-derived CTCs, EVs, and soluble proteoglycans'

Q&A 15:20-15:30

Anton Fornies Marine IDIBAPS, Spain

Proferred Paper 6: 'Cell type signatures derived from cfDNA fragmentation profiles in patients with melanoma or benign melanocytic lesions'

Q&A 15:40-15:45

Nikolas H. Stoecklein University of Dusseldorf, Germany

'From Milliliters to Liters: Diagnostic Leukapheresis Enables High-Volume Liquid Biopsy for Rare CTC Detection'

Q&A 16:05-16:15

COFFEE BREAK AND EXHIBITION

An Hendrix Ghent University, Belgium

'Extracellular vesicle-based biomarkers: from technology towards biomedical application'

Q&A 17:05-17:15

Anders Jacobsen Skanderup Genome Institute of Singapore, Singapore

'Toward Scalable Tumor-Naïve ctDNA Quantification'

Q&A 17:35-17:45

PANEL DISCUSSION

'Publication strategies and the responsible use of AI in scientific writing'

Scheduled to end at 18:30

CONFERENCE DINNER (OPTIONAL TICKETED EVENT)

Listed times are in Central European Summer Time (CEST)

EARLY POSTER VIEWING

Chair: An Hendrix

INDUSTRY SPOTLIGHT - Particle Metrix

Bertrand Damart

'ZetaView Evolution : a new edge for nanoparticle characterization'

Session 4: Liquid insights at the earliest stage: Transforming localised cancer detection and intervention

KEYNOTE LECTURE

Maximilian Diehn Stanford University, USA

'Analysis of cell-free RNA for cancer detection and characterization'

Q&A 09:30-09:45

Claus Lindbjerg Andersen Aarhus University, Denmark

'From Resection to Recurrence Prediction: The Role of Liquid Biopsy in CRC Management'

Q&A 10:05-10:15

Christopher Sng Institute of Cancer Research, UK

Proferred Paper 7: 'Augmenting circulating tumour DNA (ctDNA) recurrence prediction in resected colorectal cancer (CRC) through primary tumour genome sequencing'

Q&A 10:25-10:30

COFFEE BREAK AND EXHIBITION

Nickolas Papadopoulos John Hopkins Medicine, USA

'Quantification of disease burden in acute myeloid leukemia patients'

Q&A 11:20-11:30

Angela DeMichele Penn Medicine, USA

'ctDNA in the neoadjuvant and adjuvant management of breast cancer: the quest for clinical utility'

Q&A 11:50-12:00

SUMMARY AND CLOSE